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ABSTRACT 
Recent advances in the field of direct reprogramming have changed the way we see and study the plasticity of somatic cells. 
Many research groups worldwide are developing techniques with which one cell type is directly converted into another 
without passing through an intermediate multipotent stem cell-like state. Ectopic overexpression of transcription factors, 
microRNAs, epigenetic and metabolic regulators, even exosomal particles, have been proven sufficient in yielding a variety 
of cell types from fibroblasts, with neurons, hepatocytes, cardiomyocytes, endothelial cells and hematopoietic progenitor 
cells being amongst them. These studies have been an inspiration for creating new approaches in regenerative medicine, 
especially in the field of cardiovascular biology. Developing novel methods of regenerating the damaged myocardium and 
endothelium are crucial to millions of patients worldwide suffering from diabetes and cardiovascular disease. In the present 
study, we aim to review the progress of direct reprogramming and discuss the possible applications of this technology in 
regenerative therapy, disease modelling and drug discovery. 
FROM INDUCED PLURIPOTENT STEM CELLS 
TO DIRECT REPROGRAMMING 
In 2006, Takahashi and Yamanaka [1] reported the existence 
of the first successful line of induced pluripotent stem cells 
(iPSCs) derived from mouse fibroblasts by forcing the 
overexpression of 4 transcription factors, Oct4, Sox2, Klf4 
and c-Myc (also known as OSKM or Yamanaka factors). 
Shortly after, iPSCs were successfully derived from other 
species including humans [2], rats [3] and rhesus monkeys 
[4]. Since then, multiple groups have developed protocols 
modifying the OSKM cocktail to improve efficiency and 
address safety challenges, resulting in the generation of well-
characterised iPSCs from a variety of sources. While iPSCs 
are a valuable tool in regenerative medicine, the risk of 
tumour development makes their clinical application in 
humans challenging. Arguably, using iPSCs-derived cells 
for disease modelling, drug development and study in the lab 
is invaluable; for example, there are multiple protocols that 
efficiently produce functional cardiomyocytes and 
endothelial cell (EC) types. However, the safety of these 
cells is questioned due to the integration of foreign DNA in 
the human cells. 
HISTORY OF CELLULAR REPROGRAMMING 
The road to pluripotency has inspired the hypothesis that, 
during reprogramming, there is a short window when the 
cell is epigenetically “fluid”. Slowly but steadily, the idea of 
manipulating the cell fate during this time frame excited the 
scientific community and, thus, attempts to directly 
reprogram a somatic cell line into another commenced. In 
1987, Davis et al. [5] introduced the idea of 
transdifferentiation from fibroblasts into myoblasts via 
epigenetic modulation. Even though it did not receive the 
same amount of attention as the reprogramming attempts to 
pluripotency that took place almost 20 years later, it did 
serve as inspiration for scientists. At this point, it is very 
important to note that during these years the idea was not 
forgotten or ostracised. There are multiple publications - 
some of them now retracted - claiming that during 
embryogenesis blood cells turn into neurons or hepatic cells 
but these claims were never reproduced so the idea of direct 
reprogramming was very hard to be accepted [6]. The 
OSKM reprogramming was the catalyst of a revolution in 
the  field  that resulted in hundreds of publications  tweaking 
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and twisting every little aspect of the original idea so that the 
generation of therapeutic cells becomes a reality. 
PARTIAL REPROGRAMMING 
Moving forward, in 2011 reports of successful conversion of 
mouse fibroblasts into neural progenitors [7] revived the 
interest and in 2012 the idea of a short partial 
reprogramming was introduced, in which the cells bypassed 
the intermediate multipotent state and were directed towards 
fully functional ECs [8] that had high angiogenic ability both 
in vivo and in vitro. A year later, human smooth muscle cells 
(SMCs) were generated through the partially-induced 
pluripotent stem (PiPS) cells technology [9]. The 
combination of PiPS-ECs and PiPS-SMCs in vascular grafts 
was reported to increase the survival of SCID mice [9] in 
vivo and create a very promising mode of studying 
cardiovascular disease in vitro [10-12].  
The protocols kept evolving and shortly only two or even 
one, out of the four OSKM factors was enough to reprogram 
fibroblasts towards an EC fate. Li et al. [13] generated 
functional human ECs in a month using only Oct4 and Klf4 
while murine fibroblasts were directed into an EC fate using 
only Oct4 and small molecules [14].  
REFINING THE DIRECT REPROGRAMMING 
APPROACH TO IMPROVE EFFICIENCY 
Additional approaches towards more effective 
reprogramming have also been examined, with the OSKM 
factors left out in favour of transcription factors that are 
specific to the endpoint cell line [15]. For example, Ieda et 
al. [16] showcased the conversion of human fibroblasts into 
cardiomyocytes with Gata4, Mef2c and Tbx5 (GMT) and 
Han et al. [17] into endothelial cells with Foxo1, Er71, Klf2, 
Tal1 and Lmo2 [17]. However, in both cases the efficiency 
was quite low (5%). This led to trying out even more 
combinations where, for example, the addition of Hand2 and 
NK2 homeobox 5 (Nkx2.5) achieved a 50-fold increase in 
efficiency compared to GMT alone [18]. Other 
combinational strategies evaluated specific miRNAs (miR-1, 
miR-133, miR-208 and miR-499) for the in vitro induction 
of direct cell reprogramming of fibroblasts to 
cardiomyocytes [19]. Furthermore, reprogramming 
efficiency was also shown to be improved by modulators of 
epigenetic-related enzymes, such as DNA 
methyltransferases [20]. 
Despite all these advances, screenings for genes that regulate 
the cell fate towards a cardiovascular cell fate continued and 
eventually introduced the idea of a “master regulator” that 
plays a key role in the early development of the vessels and 
the heart [21,22]. In ECs, for example, Etv2 was shown to be 
quite promising, with several groups using it to convert 
human amniotic cells or fibroblasts into ECs [23-25]. At the 
same time, it is long known that inhibiting or activating 
certain pathways will change the cell fate. Harding et al. [26] 
proved that the MAPK and the PI3K pathways are crucial to 
EC differentiation from iPSCs with high purities (94%-97% 
CD31+ and 78%-83% VE-cadherin+) in 8 days without cell 
sorting. Cases like this showcase the importance of 
epigenetic modulation, with subsequent stabilisation of this 
state, so that it can produce functional cells. 
STABILISING THE CELL FATE 
Attempting to stabilise the cell fate in the reprogramming 
cells led to the use of small molecules either during or after 
differentiation. The use of recombinant proteins to enhance 
the activity of certain pathways is widely used, with the 
VEGF pathway being one of the most important ones due to 
its significant role in ECs; even a small amount of VEGFA 
supplement in the culture media can lead to the significant 
enhancement of EC function and morphology [27-29]. 
Currently, reprogramming with small molecules is 
investigated with breakthroughs in neuron [30] and cardiac 
[31] generation. Cases like this are distinctive and their
integration into the reprogramming technology will give rise
to protocols that have higher efficiency and, in some cases,
are shorter in duration.
CHALLENGES AND A LOOK INTO THE FUTURE 
In animal embryos, cells transition from a multi potential 
state, with the capacity to adopt multiple fates, into an 
irreversible, committed state of differentiation [32]. This is a 
phrase that was accepted as a universal truth for many years. 
Being able to rewind the clock on a committed cell line by 
manipulating the microenvironment and its genetic makeup, 
contradicts its finality and allows us to look past that: 1. 
Investigating the molecular mechanisms during 
differentiation is the key to unlocking the epigenetic 
networks at work so that a usable vascular model can be 
created. 2. Further studies, including optimization of 
vascular reprogramming in human fibroblasts, are needed. 
As the demand is high for new regenerative therapies, the 
opportunities and the potential benefits of this direct 
reprogramming approach are significant. With this final 
thought two questions remain; which approach is better? 
What is the difference between the mechanisms involved in 
the two approaches? Maybe we are not any closer to 
answering these than we were 30 years ago but studying 
how the epigenetic and metabolic profile of the cells change 
during differentiation from iPSCs to a committed cell type is 
certainly the key to discovering the missing piece of the 
puzzle of direct somatic reprogramming. The epigenetic 
changes are crucial in directing a different phenotype and 
mimicking the microenvironment of the target-cell will 
facilitate the transition. On this basis, the idea of in vivo 
reprogramming – an interesting sum of techniques, albeit 
still not proven safe [33-35] and its possible combination 
with in vitro re-modelling would create a model to study 
vascular regeneration universally. 
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